Navigation Links
Low dose antibiotic treatment of C-difficile as effective as high dose in hospital setting
Date:9/11/2013

NEW YORK (September 11, 2013) Clostridium difficile infection (CDI) treatment in a hospital setting using low dose oral vancomycin showed similar effectiveness compared to high dose, according to a new study by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University. These data were presented yesterday at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Denver.

Patients with CDI treated with vancomycin at the low dose (LD) (125 mg every 6 hours) and high dose (HD) (greater than 125mg every 6 hours) showed clinical improvements 72 hours after administration (85% and 86%, respectively).

CDI is an infection of the large bowel that can result in mild to severe symptoms including stomach pain, severe cramping, profuse diarrhea, and, in the most severe form, can lead to death. CDI is linked to 14,000 deaths each year in the United States, according to the Centers for Disease Control and Prevention.

"This study's comparable results in low dose and high dose antibiotic treatment of CDI reinforce the importance of considering new approaches to using these medications," said Philip Chung, PharmD, M.S., clinical pharmacy manager in Infectious Diseases, Montefiore Medical Center and assistant professor of medicine, Department of Medicine (Infectious Diseases), Einstein. "Antibiotic stewardship is an important focus in hospitals today. We are using our study findings to develop treatment guidelines that encourage low dose treatment."

Comparable results in the LD and HD groups were shown in secondary endpoints, including rates of clinical improvement at end of therapy or time of hospital discharge (93% and 95%, respectively), in-hospital mortality (15% and 23%), re-treatment (4% and 6%), and 30-day readmission (34% and 24%).

"Montefiore is committed to the appropriate use of antibiotics through a multi-disciplinary Antimicrobial Stewardship Team that supports better patient care and safety, improved clinical outcomes and reduced resistance and healthcare-acquired infections such as CDI," said infectious diseases specialist Belinda Ostrowsky, M.D., M.P.H., director, Antibiotic Stewardship Program, Montefiore and associate professor of clinical medicine, Department of Medicine (Infectious Diseases), Einstein. "Based on our study results, we know making small changes can make a big difference without impacting patient care in a hospital setting. These results are encouraging and we plan to continue exploring other ways to impact antibiotic use."

This retrospective study included 300 patients (197 LD, 103 HD) hospitalized at Montefiore between 2006 and 2010 who had a diagnosis of diarrhea associated CDI and received at least 72 hours of oral vancomycin. Medical records of eligible patients were reviewed for demographics, clinical and laboratory parameters for resolution of infection, other antibiotics prescribed during treatment of CDI, death during hospitalization and hospital readmission within 30-days after discharge.

In addition to Dr. Chung and Dr. Ostrowsky, other researchers involved in the study are Montefiore pharmacist Monica Ramirez, PharmD, and clinical pharmacy managers Angela Cheng, PharmD, (also assistant professor of medicine, Department of Medicine (Cardiology) at Einstein), Toshiba Morgan-Joseph, PharmD, and Yi Guo, PharmD, (also assistant professor of medicine, Department of Medicine (Infectious Disease) at Einstein).


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Antibiotics Linked to Retinal Detachment Risk
2. Researchers find evidence of banned antibiotics in poultry products
3. Study Finds Antibiotics Best for Appendicitis
4. FDA Seeks to Limit Antibiotics in Animal Feed
5. Probiotic Products May Prevent Antibiotic-Linked Diarrhea
6. Study Links Antibiotic to Slight Rise in Heart Patients Death Risk
7. Study shows antibiotic improves respiratory function in lung transplant patients
8. Antibiotic-Resistant Gonorrhea Spreading: WHO
9. A non-antibiotic approach for treating urinary tract infections
10. Trivedi Beef, LLC Announces Breakthrough Beef Industry Data without the use of Antibiotic Drugs, Hormones or Steroids
11. Study examines role of seasonal prescribing changes in antibiotic resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the National Sleep Foundation , ... not the only cause of the sunken-eye look, which can include dark circles or ... in poor health are likely due to genetics, dehydration, allergies, and losing fat beneath ...
(Date:3/23/2017)... NC (PRWEB) , ... March 23, 2017 , ... Inflow ... ride). Life is serious so build on a solid foundation. As experts in ... priority vital information that is coming soon. Inflownomics deliver ripe, fresh, clean & refreshing ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... stands with all Americans facing life-altering and fatal diseases in opposition to the ... shortsighted decisions that would eviscerate care, services, and hope for the most vulnerable ...
(Date:3/23/2017)... (PRWEB) , ... March 23, ... ... Reports: Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 ... p.m. ET, http://www.fdanews.com/mdclineval                  , How will the new EU MDR ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... RADNOR, Pennsylvania , 22 de marzo de ... proveedor independiente global líder de soluciones de productos ... ha anunciado hoy que ha adquirido EPL Archives, ... apoya a los clientes en todo el ciclo ... y comercialización ofreciendo una muestra de archivo, almacenamiento ...
(Date:3/22/2017)... Israel, March 22, 2017  DarioHealth Corp. (NASDAQ: ... mobile health and big data solutions, today reported ... twelve month period ended December 31, 2016. ... of $2.8 million, increased 241% compared to the ... revenue growth throughout the entire year  ...
(Date:3/22/2017)... 2017 Ampio Pharmaceuticals, Inc. (NYSE MKT: ... a low molecular weight fraction of human serum ... is re-issuing its previous release that was made on ... are required under the NYSE MKT Company Guide ... disclosures along with the previously disclosed update of ...
Breaking Medicine Technology: